Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
NCT05702905 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2024-03-25
Summary
To investigate the efficacy of semaglutide in obese infertile women of childbearing age with polycystic ovary syndrome (PCOS), we design this prospective, randomized, open and controlled study. 75 obese infertile PCOS patients will be recruited and randomized into three groups: metformin, semaglutide and metformin+semaglutide, on the basis of calorie-restricted diet and physical exercise. All subjects will be treated for 12 weeks, and then stop taking the drug for at least 8 weeks to initiate ovulation induction or ovulation induction combined with artificial insemination. All subjects will be followed up for 24 weeks for pregnancy outcome. The primary endpoint of the study is the percentage of weight loss at 12 weeks of treatment. The secondary endpoints include HOMA-IR and androgen levels at 12 weeks of treatment, ovulation rate at 24 weeks of follow-up, clinical pregnancy rate and cumulative pregnancy rate, and depression, anxiety, diet and quality of life scores at 12 weeks of treatment.
Conditions
- PCOS (Polycystic Ovary Syndrome)
- Semaglutide
Interventions
- DRUG
-
Metformin Hydrochloride 500 MG
Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
- DRUG
-
Semaglutide, 1.34 mg/mL
Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
- DRUG
-
Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG
Both Semaglutide injection and Metformin oral tablet will be administered as described above.
- BEHAVIORAL
-
calorie-restricted diet
All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
- BEHAVIORAL
-
physical exercise
All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
Sponsors & Collaborators
-
Peking University First Hospital
lead OTHER
Principal Investigators
-
Tingting Zhang, M.D. · Peking University First Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 22 Years
- Max Age
- 40 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-09
- Primary Completion
- 2024-12-31
- Completion
- 2025-06-30
Countries
- China
Study Locations
More Related Trials
-
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
NCT06775093 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.
NCT04969627 ·Status: COMPLETED ·Phase: PHASE4
-
CRD vs. Met in Patients With Obese PCOS Infertility
NCT06049186 ·Status: RECRUITING ·Phase: NA
-
SGLT2 Inhibitors in Treating Patients With PCOS
NCT05966792 ·Status: COMPLETED ·Phase: NA
-
Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients
NCT03034941 ·Status: COMPLETED ·Phase: PHASE4
-
Treating PCOS With Digital Intervention vs. Metformin
NCT05386706 ·Status: COMPLETED ·Phase: NA
-
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
NCT03566225 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome
NCT00679679 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
NCT04029272 ·Status: UNKNOWN ·Phase: PHASE4
-
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
NCT05952882 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome
NCT01366391 ·Status: UNKNOWN ·Phase: PHASE4
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT03919929 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome
NCT03989024 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients
NCT05463627 ·Status: UNKNOWN
-
The Effect of a Liraglutide on IVF in Obese PCOS
NCT03353948 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
NCT04876027 ·Status: COMPLETED ·Phase: PHASE4
-
Chiglitazar/Metformin in Non-obese Women With PCOS
NCT06125587 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
NCT03151005 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
NCT05965908 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM
NCT05760677 ·Status: UNKNOWN ·Phase: PHASE1
-
Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
NCT01909141 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study to Assess the Effect of Metformin Supplementation on IVF Outcome in Patients With Polycystic Ovarian Syndrome.
NCT03086005 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women
NCT02910817 ·Status: COMPLETED ·Phase: NA
-
Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF
NCT01438190 ·Status: UNKNOWN ·Phase: PHASE4
-
Research of Exenatide for Overweight/Obese PCOS Patients With IGR
NCT03352869 ·Status: COMPLETED ·Phase: PHASE4